Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy response, BTK C481 mutation status, comorbidities, drug interaction profiles, dosing convenience, and adverse effect considerations, with noncovalent inhibitors offering particular benefit for those with BTK mutations or intolerance to covalent agents.

EP: 1.Fixed-Duration Options for CLL

EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study

EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

EP: 4.Sequencing Considerations in Relapsed/Refractory CLL

Now Viewing

EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

Video content above is prompted by the following:

• What key factors influence your decision when selecting among the available BTK inhibitors for patients with R/R CLL?
• What clinical or molecular features help identify patients with R/R CLL who are most likely to benefit from noncovalent BTK inhibitors compared with covalent BTK inhibitors?

Related Videos

Related Content

Advertisement

January 23rd 2025

Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care

Brooke McCormick

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 22nd 2025

Combination of Dolutegravir, Lamivudine Effective in People Living With HIV

Julia Bonavitacola

Real-world analyses have confirmed the efficacy of the 2-drug regimen of dolutegravir and lamivudine in treating HIV, confirming phase 3 testing results.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 21st 2025

Obesity Metrics May Better Reflect CRC Link Than BMI

Pearl Steinzor

Waist circumference and waist-to-hip ratio show stronger links to colorectal cancer (CRC) than body mass index (BMI), a new study has found.

January 19th 2025

AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes

Brooke McCormick

Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.

Related Content

Advertisement

January 23rd 2025

Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care

Brooke McCormick

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 22nd 2025

Combination of Dolutegravir, Lamivudine Effective in People Living With HIV

Julia Bonavitacola

Real-world analyses have confirmed the efficacy of the 2-drug regimen of dolutegravir and lamivudine in treating HIV, confirming phase 3 testing results.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 21st 2025

Obesity Metrics May Better Reflect CRC Link Than BMI

Pearl Steinzor

Waist circumference and waist-to-hip ratio show stronger links to colorectal cancer (CRC) than body mass index (BMI), a new study has found.

January 19th 2025

AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes

Brooke McCormick

Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.